{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:38:01Z","timestamp":1791927481274,"version":"4.3.4"},"reference-count":267,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Postmenopausal women experience ongoing loss of bone mass, with resulting increases in the risk of fracture. This review describes the nature of postmenopausal bone loss, the definition of osteoporosis, and the current status of fracture risk estimation, which is pivotal in osteoporosis management. Important lifestyle measures include taking a balanced diet to maintain a healthy weight throughout life, safe physical activity, not smoking, and moderating alcohol intake. Severe vitamin D deficiency accelerates bone loss so should be avoided. Falls prevention becomes increasingly important with age, since falls cause most fractures. Pharmaceuticals to increase bone mass and prevent fractures either act by inhibiting bone resorption or by stimulating bone formation. Bisphosphonates are the most widely used antiresorptives, often taken as weekly oral doses. The intravenous bisphosphonate, zoledronate, has a long duration of action with effects on bone turnover, density, and fractures over a decade after a single dose. It is increasingly used in both prevention and treatment of osteoporosis. Denosumab is effective in preventing fractures but has a rapid offset of effect after its cessation. Some anabolic agents act via the PTH1 receptor, producing substantial increases in spine bone density but are not yet proven to prevent hip fractures. Romosozumab is a monoclonal antibody directed at sclerostin. It has both anabolic and antiresorptive effects and shows broad antifracture efficacy. Anabolics are used for 1 to 2 years in those with high fracture risk, before transition to long-term antiresorptive therapy. Treatment sequence options are discussed but more research is needed to establish which provide optimal fracture reduction.<\/jats:p>","DOI":"10.1210\/endrev\/bnag006","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:36:25Z","timestamp":1771936585000},"page":"468-495","source":"Crossref","is-referenced-by-count":8,"title":["Management of postmenopausal osteoporosis"],"prefix":"10.1210","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6021-5458","authenticated-orcid":false,"given":"Ian R","family":"Reid","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Auckland , Auckland 1142 ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0465-2674","authenticated-orcid":false,"given":"Mark J","family":"Bolland","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Auckland , Auckland 1142 ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"issue":"6","key":"2026071419565723500_bnag006-B1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/0002-9343(93)90218-E","article-title":"Consensus development conference\u2014diagnosis, prophylaxis, and treatment of osteoporosis\u2014rapid publication","volume":"94","author":"Peck","year":"1993","journal-title":"Am J Med"},{"issue":"4","key":"2026071419565723500_bnag006-B2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00198-005-0027-4","article-title":"The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the national osteoporosis risk assessment (NORA)","volume":"17","author":"Siris","year":"2006","journal-title":"Osteoporos Int"},{"issue":"8","key":"2026071419565723500_bnag006-B3","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","article-title":"Perspective: the diagnosis of osteoporosis","volume":"9","author":"Kanis","year":"1994","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2026071419565723500_bnag006-B4","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","article-title":"Bone mineral density thresholds for pharmacological intervention to prevent fractures","volume":"164","author":"Siris","year":"2004","journal-title":"Arch Int Med"},{"key":"2026071419565723500_bnag006-B5","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bone.2018.06.004","article-title":"Fracture incidence and secular trends between 1989 and 2013 in a population based cohort: the Rotterdam study","volume":"114","author":"Trajanoska","year":"2018","journal-title":"Bone"},{"issue":"8","key":"2026071419565723500_bnag006-B6","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1210\/jc.2018-02614","article-title":"Two-thirds of all fractures are not attributable to osteoporosis and advancing age: implications for fracture prevention","volume":"104","author":"Mai","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026071419565723500_bnag006-B7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00223-018-0476-3","article-title":"OFELIA: prevalence of osteoporosis in fragility fracture patients","volume":"104","author":"Tei","year":"2019","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"2026071419565723500_bnag006-B8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00198-022-06580-y","article-title":"Doctors won\u2019t treat patients for conditions they don\u2019t have","volume":"34","author":"Reid","year":"2023","journal-title":"Osteoporos Int"},{"issue":"6","key":"2026071419565723500_bnag006-B9","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1001\/jama.2024.27154","article-title":"Screening for osteoporosis to prevent fractures: US preventive services task force recommendation statement","volume":"333","author":"U. S. Preventive Services Task Force","year":"2025","journal-title":"JAMA"},{"issue":"6","key":"2026071419565723500_bnag006-B10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1001\/jama.2024.21653","article-title":"Screening for osteoporosis to prevent fractures: a systematic evidence review for the US preventive services task force","volume":"333","author":"Kahwati","year":"2025","journal-title":"JAMA"},{"key":"2026071419565723500_bnag006-B11","first-page":"1022","volume-title":"DeGroot's Endocrinology","author":"Reid","year":"2022"},{"issue":"3","key":"2026071419565723500_bnag006-B12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/jbmr\/zjae201","article-title":"The relationship between baseline BMD and fracture incidence in the placebo groups of RCTs using individual patient data from the FNIH-ASBMR-SABRE project","volume":"40","author":"Schini","year":"2025","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2026071419565723500_bnag006-B13","doi-asserted-by":"crossref","first-page":"e2329253","DOI":"10.1001\/jamanetworkopen.2023.29253","article-title":"Adjusting FRAX estimates of fracture probability based on a positive vertebral fracture assessment","volume":"6","author":"Ye","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"3","key":"2026071419565723500_bnag006-B14","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40618-023-02219-9","article-title":"An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis","volume":"47","author":"Schini","year":"2024","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"2026071419565723500_bnag006-B15","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/jbmr.2054","article-title":"Intervals between bone density testing","volume":"29","author":"Reid","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2026071419565723500_bnag006-B16","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/jbmr.3717","article-title":"Performance of FRAX and FRAX-based treatment thresholds in women aged 40 years and older: the Manitoba BMD registry","volume":"34","author":"Crandall","year":"2019","journal-title":"J Bone Miner Res"},{"key":"2026071419565723500_bnag006-B17","doi-asserted-by":"crossref","first-page":"E3427","DOI":"10.1136\/bmj.e3427","article-title":"Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study","volume":"344","author":"Hippisley-Cox","year":"2012","journal-title":"BMJ"},{"key":"2026071419565723500_bnag006-B18","doi-asserted-by":"crossref","first-page":"e8669","DOI":"10.1136\/bmj.e8669","article-title":"Discrepancies in predicted fracture risk in elderly people","volume":"346","author":"Bolland","year":"2013","journal-title":"BMJ"},{"issue":"12","key":"2026071419565723500_bnag006-B19","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/jbmr.4896","article-title":"Effect of race\/ethnicity on United States FRAX calculations and treatment qualification: a registry-based study","volume":"38","author":"Leslie","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2026071419565723500_bnag006-B20","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s00198-024-07162-w","article-title":"Race-specific FRAX models are evidence-based and support equitable care: a response to the ASBMR task force report on clinical algorithms for fracture risk","volume":"35","author":"Kanis","year":"2024","journal-title":"Osteoporos Int"},{"issue":"11","key":"2026071419565723500_bnag006-B21","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1007\/s00198-005-1863-y","article-title":"Body mass index as a predictor of fracture risk: a meta-analysis","volume":"16","author":"De Laet","year":"2005","journal-title":"Osteoporos Int"},{"issue":"1","key":"2026071419565723500_bnag006-B22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jbmr.2017","article-title":"A meta-analysis of the association of fracture risk and body mass index in women","volume":"29","author":"Johansson","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2026071419565723500_bnag006-B23","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(21)00119-4","article-title":"Nutritional intake and bone health","volume":"9","author":"Rizzoli","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026071419565723500_bnag006-B24","doi-asserted-by":"crossref","first-page":"n2364","DOI":"10.1136\/bmj.n2364","article-title":"Effect of dietary sources of calcium and protein on hip fractures and falls in older adults in residential care: cluster randomised controlled trial","volume":"375","author":"Iuliano","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"2026071419565723500_bnag006-B25","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00198-023-07012-1","article-title":"A meta-analysis of previous falls and subsequent fracture risk in cohort studies","volume":"35","author":"Vandenput","year":"2024","journal-title":"Osteoporos Int"},{"issue":"6","key":"2026071419565723500_bnag006-B26","doi-asserted-by":"crossref","first-page":"afac105","DOI":"10.1093\/ageing\/afac105","article-title":"Fall prevention in older people: past, present and future","volume":"51","author":"Close","year":"2022","journal-title":"Age Ageing"},{"key":"2026071419565723500_bnag006-B27","doi-asserted-by":"crossref","first-page":"e066991","DOI":"10.1136\/bmj-2021-066991","article-title":"Multifactorial falls prevention programme compared with usual care in UK care homes for older people: multicentre cluster randomised controlled trial with economic evaluation","volume":"375","author":"Logan","year":"2021","journal-title":"BMJ"},{"issue":"2","key":"2026071419565723500_bnag006-B28","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S2213-8587(19)30351-1","article-title":"Physical activity and skeletal health in adults","volume":"8","author":"Cauley","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"2026071419565723500_bnag006-B29","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/bjsports-2019-101512","article-title":"Exercise for preventing falls in older people living in the community: an abridged Cochrane systematic review","volume":"54","author":"Sherrington","year":"2020","journal-title":"Br J Sports Med"},{"issue":"10329","key":"2026071419565723500_bnag006-B30","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0140-6736(21)02646-5","article-title":"Drug therapy for osteoporosis in older adults","volume":"399","author":"Reid","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"2026071419565723500_bnag006-B31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1809944","article-title":"Vitamin D supplements and prevention of cancer and cardiovascular disease","volume":"380","author":"Manson","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"2026071419565723500_bnag006-B32","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1001\/jamacardio.2017.0175","article-title":"Effect of monthly high-dose vitamin D supplementation on cardiovascular disease: the vitamin D assessment (ViDA) study (a randomized controlled trial)","volume":"2","author":"Scragg","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"18","key":"2026071419565723500_bnag006-B33","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1001\/jama.2020.16909","article-title":"Effect of vitamin D supplementation, Omega-3 fatty acid supplementation, or a strength-training exercise program on clinical outcomes in older adults: the DO-HEALTH randomized clinical trial","volume":"324","author":"Bischoff-Ferrari","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"2026071419565723500_bnag006-B34","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S2213-8587(21)00345-4","article-title":"The D-health trial: a randomised controlled trial of the effect of vitamin D on mortality","volume":"10","author":"Neale","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9912","key":"2026071419565723500_bnag006-B35","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0140-6736(13)61647-5","article-title":"Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis","volume":"383","author":"Reid","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"2026071419565723500_bnag006-B36","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/jbmr.3958","article-title":"Effects of supplemental vitamin D on bone health outcomes in women and men in the VITamin D and OmegA-3 TriaL (VITAL)","volume":"35","author":"LeBoff","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2026071419565723500_bnag006-B37","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1210\/clinem\/dgae312","article-title":"A systematic review supporting the Endocrine Society clinical practice guidelines on vitamin D","volume":"109","author":"Shah","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026071419565723500_bnag006-B38","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S2213-8587(23)00063-3","article-title":"The effect of monthly vitamin D supplementation on fractures: a tertiary outcome from the population-based, double-blind, randomised, placebo-controlled D-health trial","volume":"11","author":"Waterhouse","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6936","key":"2026071419565723500_bnag006-B39","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/bmj.308.6936.1081","article-title":"Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women","volume":"308","author":"Chapuy","year":"1994","journal-title":"BMJ"},{"issue":"23","key":"2026071419565723500_bnag006-B40","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJM199212033272305","article-title":"Vitamin-D3 and calcium to prevent hip fractures in elderly women","volume":"327","author":"Chapuy","year":"1992","journal-title":"N Engl J Med"},{"issue":"4","key":"2026071419565723500_bnag006-B41","doi-asserted-by":"crossref","first-page":"400","DOI":"10.7326\/0003-4819-124-4-199602150-00003","article-title":"Vitamin D supplementation and fracture incidence in elderly persons\u2014a randomized, placebo-controlled clinical trial","volume":"124","author":"Lips","year":"1996","journal-title":"Ann Intern Med"},{"issue":"7","key":"2026071419565723500_bnag006-B42","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJMoa055218","article-title":"Calcium plus vitamin D supplementation and the risk of fractures","volume":"354","author":"Jackson","year":"2006","journal-title":"N Engl J Med"},{"issue":"8","key":"2026071419565723500_bnag006-B43","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1210\/clinem\/dgae322","article-title":"Vitamin D insufficiency and epistemic humility: an endocrine society guideline communication","volume":"109","author":"McCartney","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071419565723500_bnag006-B44","doi-asserted-by":"crossref","first-page":"355","DOI":"10.15537\/1658-3175.2353","article-title":"Bone mineral density and bone scintigraphy in adult Saudi female patients with osteomalacia","volume":"25","author":"El-Desouki","year":"2004","journal-title":"Saudi Med J"},{"issue":"5","key":"2026071419565723500_bnag006-B45","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/joim.12651","article-title":"Effect of monthly high-dose vitamin D on bone density in community-dwelling older adults substudy of a randomized controlled trial","volume":"282","author":"Reid","year":"2017","journal-title":"J Intern Med"},{"issue":"8","key":"2026071419565723500_bnag006-B46","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/jbmr.3442","article-title":"25-Hydroxyvitamin D threshold for the effects of vitamin D supplements on bone density: secondary analysis of a randomized controlled trial","volume":"33","author":"Macdonald","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026071419565723500_bnag006-B47","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1359\/jbmr.061008","article-title":"Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study","volume":"22","author":"McCloskey","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2026071419565723500_bnag006-B48","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2407031","article-title":"Fracture prevention with infrequent zoledronate in women 50 to 60 years of age","volume":"392","author":"Bolland Mark","year":"2025","journal-title":"N Engl J Med"},{"issue":"8205","key":"2026071419565723500_bnag006-B49","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0140-6736(80)92592-1","article-title":"Prevention of spinal osteoporosis in oophorectomised women","volume":"316","author":"Lindsay","year":"1980","journal-title":"Lancet"},{"issue":"8","key":"2026071419565723500_bnag006-B50","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/jama.2019.11889","article-title":"Effect of high-dose vitamin D supplementation on volumetric bone density and bone strength: a randomized clinical TrialEffect of high-dose vitamin D supplementation on volumetric bone density and bone StrengthEffect of high-dose vitamin D supplementation on volumetric bone density and bone strength","volume":"322","author":"Burt","year":"2019","journal-title":"JAMA"},{"issue":"18","key":"2026071419565723500_bnag006-B51","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1001\/jama.2010.594","article-title":"Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial","volume":"303","author":"Sanders","year":"2010","journal-title":"JAMA"},{"key":"2026071419565723500_bnag006-B52","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jsbmb.2017.03.015","article-title":"Medium doses of daily vitamin D decrease falls and higher doses of daily vitamin D3 increase falls: a randomized clinical trial","volume":"173","author":"Smith","year":"2017","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"5","key":"2026071419565723500_bnag006-B53","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1210\/er.2016-1070","article-title":"Vitamin D-mediated hypercalcemia: mechanisms, diagnosis, and treatment","volume":"37","author":"Tebben","year":"2016","journal-title":"Endocrine Rev"},{"issue":"29","key":"2026071419565723500_bnag006-B54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta24290","article-title":"Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation","volume":"24","author":"Davis","year":"2020","journal-title":"Health Technol Assess"},{"issue":"5","key":"2026071419565723500_bnag006-B55","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"issue":"2","key":"2026071419565723500_bnag006-B56","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"24","key":"2026071419565723500_bnag006-B57","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment\u2014the fracture intervention trial long-term extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"2026071419565723500_bnag006-B58","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00044011-200626020-00002","article-title":"Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis\u2014results of FACTS-international","volume":"26","author":"Reid","year":"2006","journal-title":"Clin Drug Invest"},{"issue":"3","key":"2026071419565723500_bnag006-B59","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","article-title":"Fracture risk remains reduced one year after discontinuation of risedronate","volume":"19","author":"Watts","year":"2008","journal-title":"Osteoporos Int"},{"issue":"6","key":"2026071419565723500_bnag006-B60","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00198-018-4460-6","article-title":"Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density","volume":"29","author":"Naylor","year":"2018","journal-title":"Osteoporos Int"},{"issue":"6 Pt 1","key":"2026071419565723500_bnag006-B61","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/01.GME.0000123641.76105.B5","article-title":"Changes in bone density and turnover after alendronate or estrogen withdrawal","volume":"11","author":"Wasnich","year":"2004","journal-title":"Menopause"},{"issue":"3","key":"2026071419565723500_bnag006-B62","doi-asserted-by":"crossref","first-page":"335","DOI":"10.7326\/M21-2512","article-title":"Comparative fracture risk during osteoporosis drug holidays after long-term risedronate versus alendronate therapy: a propensity score-matched cohort study","volume":"175","author":"Hayes","year":"2022","journal-title":"Ann Intern Med"},{"issue":"6","key":"2026071419565723500_bnag006-B63","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00198-003-1399-y","article-title":"Pharmacovigilance study of alendronate in England","volume":"14","author":"Biswas","year":"2003","journal-title":"Osteoporos Int"},{"issue":"10","key":"2026071419565723500_bnag006-B64","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00198-021-05907-5","article-title":"Alendronate use in older patients with reduced renal function: challenges and opportunities in clinical practice","volume":"32","author":"Naganathar","year":"2021","journal-title":"Osteoporos Int"},{"issue":"7","key":"2026071419565723500_bnag006-B65","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/jbmr.4573","article-title":"Oral bisphosphonates are associated with increased risk of severe acute kidney injury in elderly patients with complex health needs: a self-controlled case series in the UK","volume":"37","author":"Oda","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2026071419565723500_bnag006-B66","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/jbmr.4235","article-title":"Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a bi-national cohort analysis","volume":"36","author":"Robinson","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026071419565723500_bnag006-B67","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/ndt\/gfaa192","article-title":"European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D","volume":"36","author":"Evenepoel","year":"2021","journal-title":"Nephrol Dialysis Transplant"},{"issue":"3","key":"2026071419565723500_bnag006-B68","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/bcp.15559","article-title":"Effect of oral zoledronate administration on bone turnover in older women","volume":"89","author":"Reid","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"2026071419565723500_bnag006-B69","doi-asserted-by":"crossref","first-page":"115390","DOI":"10.1016\/j.bone.2020.115390","article-title":"Zoledronate","volume":"137","author":"Reid","year":"2020","journal-title":"Bone"},{"issue":"9","key":"2026071419565723500_bnag006-B70","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med"},{"issue":"18","key":"2026071419565723500_bnag006-B71","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"2026071419565723500_bnag006-B72","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-pivotal fracture trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2026071419565723500_bnag006-B73","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/jbmr.2442","article-title":"The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-pivotal fracture trial (PFT)","volume":"30","author":"Black","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"18","key":"2026071419565723500_bnag006-B74","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"2026071419565723500_bnag006-B75","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1210\/jc.2012-2868","article-title":"Reduction in the risk of clinical fractures after a single dose of zoledronic acid 5 milligrams","volume":"98","author":"Reid","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"36","key":"2026071419565723500_bnag006-B76","doi-asserted-by":"crossref","first-page":"E1130","DOI":"10.1503\/cmaj.161207","article-title":"Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial","volume":"189","author":"Grey","year":"2017","journal-title":"CMAJ"},{"issue":"25","key":"2026071419565723500_bnag006-B77","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture prevention with zoledronate in older women with osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"2026071419565723500_bnag006-B78","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/joim.12901","article-title":"Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial","volume":"286","author":"Reid","year":"2019","journal-title":"J Intern Med"},{"key":"2026071419565723500_bnag006-B79","doi-asserted-by":"publisher","author":"Reid","DOI":"10.1093\/jbmr\/zjag012"},{"issue":"4","key":"2026071419565723500_bnag006-B80","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S2213-8587(24)00003-2","article-title":"Duration of fracture prevention after zoledronate treatment in women with osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years","volume":"12","author":"Reid","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2026071419565723500_bnag006-B81","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/AOG.0b013e3181bdce0a","article-title":"Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass a randomized controlled trial","volume":"114","author":"McClung","year":"2009","journal-title":"Obstet Gynecol"},{"issue":"1","key":"2026071419565723500_bnag006-B82","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.4453","article-title":"Bone mineral density and bone turnover 10 years after a single 5mg dose or two 5-yearly lower doses of zoledronate in osteopenic older women: an open-label extension of a randomized controlled trial","volume":"37","author":"Grey","year":"2022","journal-title":"J Bone Miner Res"},{"key":"2026071419565723500_bnag006-B83","doi-asserted-by":"publisher","first-page":"e1080","DOI":"10.1210\/clinem\/dgaf569","article-title":"Antifracture efficacy of 5- or 10-yearly zoledronate in women aged 50 to 60 years: secondary analyses of a randomized trial","volume":"111","author":"Bolland","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026071419565723500_bnag006-B84","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1210\/jc.2010-0597","article-title":"Characterization of and risk factors for the acute-phase response after zoledronic acid","volume":"95","author":"Reid","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026071419565723500_bnag006-B85","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ophtha.2012.10.028","article-title":"The incidence of acute anterior uveitis after intravenous zoledronate","volume":"120","author":"Patel","year":"2013","journal-title":"Ophthalmology"},{"issue":"2","key":"2026071419565723500_bnag006-B86","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00198-011-1563-8","article-title":"Treatment with Acetaminophen\/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5mg","volume":"23","author":"Wark","year":"2012","journal-title":"Osteoporos Int"},{"issue":"8","key":"2026071419565723500_bnag006-B87","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s00198-010-1448-2","article-title":"Effect of Acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid","volume":"22","author":"Silverman","year":"2011","journal-title":"Osteoporos Int"},{"issue":"5","key":"2026071419565723500_bnag006-B88","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/jbmr.4802","article-title":"Effect of a three-day course of dexamethasone on acute phase response following treatment with zoledronate: a randomized controlled trial","volume":"38","author":"Murdoch","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2026071419565723500_bnag006-B89","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00198-021-06160-6","article-title":"Evaluation of estimated glomerular function (eGFR) versus creatinine clearance (CrCl) to predict acute kidney injury when using zoledronate for the treatment of osteoporosis","volume":"33","author":"Schini","year":"2022","journal-title":"Osteoporos Int"},{"issue":"8","key":"2026071419565723500_bnag006-B90","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s00198-022-06427-6","article-title":"Safety of zoledronate in older patients at high risk of fracture with reduced renal function","volume":"33","author":"Sahota","year":"2022","journal-title":"Osteoporos Int"},{"issue":"10","key":"2026071419565723500_bnag006-B91","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/jbmr.149","article-title":"Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies","volume":"25","author":"Reid","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2026071419565723500_bnag006-B92","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071419565723500_bnag006-B93","doi-asserted-by":"crossref","first-page":"115830","DOI":"10.1016\/j.bone.2020.115830","article-title":"Risk factors for vertebral fractures and bone loss after denosumab discontinuation: a real-world observational study","volume":"144","author":"Everts-Graber","year":"2021","journal-title":"Bone"},{"issue":"8","key":"2026071419565723500_bnag006-B94","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"2026071419565723500_bnag006-B95","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl 2","key":"2026071419565723500_bnag006-B96","first-page":"56","article-title":"Early findings from Prolia\u00ae post-marketing safety surveillance for atypical femoral fracture, osteonecrosis of the jaw, severe symptomatic hypocalcemia, and anaphylaxis","volume":"25","author":"Geller","year":"2014","journal-title":"Osteoporos Int"},{"issue":"1","key":"2026071419565723500_bnag006-B97","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s11657-023-01306-x","article-title":"Treatment of osteoporosis with denosumab in patients with decreased kidney function","volume":"18","author":"Svendsen","year":"2023","journal-title":"Arch Osteoporos"},{"issue":"7","key":"2026071419565723500_bnag006-B98","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/clinem\/dgae721","article-title":"Dose-specific effects of denosumab on serum calcium levels in patients with osteoporosis and various renal functions","volume":"110","author":"Sun","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026071419565723500_bnag006-B99","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jama.2023.28239","article-title":"Severe hypocalcemia with denosumab among older female dialysis-dependent patients","volume":"331","author":"Bird","year":"2024","journal-title":"JAMA"},{"issue":"9","key":"2026071419565723500_bnag006-B100","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/jbmr.4335","article-title":"Fractures after denosumab discontinuation: a retrospective study of 797 cases","volume":"36","author":"Burckhardt","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026071419565723500_bnag006-B101","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00223-018-0389-1","article-title":"Vertebral fractures following denosumab discontinuation in patients with prolonged exposure to bisphosphonates","volume":"103","author":"Tripto-Shkolnik","year":"2018","journal-title":"Calcif Tissue Int"},{"issue":"11","key":"2026071419565723500_bnag006-B102","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/jbmr.4705","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses","volume":"37","author":"Cosman","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2026071419565723500_bnag006-B103","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/joim.13354","article-title":"Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: a population-based cohort study","volume":"290","author":"Fu","year":"2021","journal-title":"J Int Med"},{"issue":"6","key":"2026071419565723500_bnag006-B104","doi-asserted-by":"crossref","first-page":"946","DOI":"10.3803\/EnM.2024.2047","article-title":"Association of delayed denosumab dosing with increased risk of fractures: a population-based retrospective study","volume":"39","author":"Kim","year":"2024","journal-title":"Endocrinol Metab (Seoul, Korea)"},{"issue":"6","key":"2026071419565723500_bnag006-B105","doi-asserted-by":"crossref","first-page":"ziaf061","DOI":"10.1093\/jbmrpl\/ziaf061","article-title":"Real-world differences in denosumab persistence, reinitiation, and switching among cohorts of older adults in Canada and the United States","volume":"9","author":"Hayes","year":"2025","journal-title":"JBMR Plus"},{"issue":"11","key":"2026071419565723500_bnag006-B106","doi-asserted-by":"crossref","first-page":"e2443879","DOI":"10.1001\/jamanetworkopen.2024.43879","article-title":"What to do when denosumab is stopped?","volume":"7","author":"Watts","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"12","key":"2026071419565723500_bnag006-B107","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s00198-024-07213-2","article-title":"One versus 2 years of alendronate following denosumab: the CARD extension","volume":"35","author":"Tsai","year":"2024","journal-title":"Osteoporos Int"},{"issue":"10","key":"2026071419565723500_bnag006-B108","doi-asserted-by":"crossref","first-page":"e1817","DOI":"10.1210\/clinem\/dgae224","article-title":"Zoledronate after denosumab discontinuation: is repeated administrations more effective than single infusion?","volume":"109","author":"Grassi","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026071419565723500_bnag006-B109","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00198-022-06648-9","article-title":"Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study","volume":"34","author":"Tutaworn","year":"2023","journal-title":"Osteoporos Int"},{"issue":"1","key":"2026071419565723500_bnag006-B110","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00223-025-01364-y","article-title":"Impact of zoledronic acid on bone mineral density and trabecular score following denosumab discontinuation in older adults in long-term care","volume":"116","author":"Haeri","year":"2025","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"2026071419565723500_bnag006-B111","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00198-023-06932-2","article-title":"The comparison of alendronate and raloxifene after denosumab (CARD) study: a comparative efficacy trial","volume":"35","author":"Ramchand","year":"2024","journal-title":"Osteoporos Int"},{"issue":"11","key":"2026071419565723500_bnag006-B112","doi-asserted-by":"crossref","first-page":"e2443899","DOI":"10.1001\/jamanetworkopen.2024.43899","article-title":"Zoledronate sequential therapy after denosumab discontinuation to prevent bone mineral density reduction: a randomized clinical trial","volume":"7","author":"Lee","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"9999","key":"2026071419565723500_bnag006-B113","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"2026071419565723500_bnag006-B114","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women\u2014principal results from the Women's health initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"issue":"13","key":"2026071419565723500_bnag006-B115","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jama.297.13.1465","article-title":"Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause","volume":"297","author":"Rossouw","year":"2007","journal-title":"JAMA"},{"issue":"3","key":"2026071419565723500_bnag006-B116","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/aje\/kwaa210","article-title":"Randomized trial evaluation of the benefits and risks of menopausal hormone therapy among women 50-59 years of age","volume":"190","author":"Prentice","year":"2021","journal-title":"Am J Epidemiol"},{"issue":"1","key":"2026071419565723500_bnag006-B117","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S2213-8587(24)00270-5","article-title":"Is it time to revisit the recommendations for initiation of menopausal hormone therapy?","volume":"13","author":"Taylor","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"2026071419565723500_bnag006-B118","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa0800743","article-title":"The effects of tibolone in older postmenopausal women","volume":"359","author":"Cummings","year":"2008","journal-title":"N Engl J Med"},{"issue":"7","key":"2026071419565723500_bnag006-B119","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene -results from a 3-year randomized clinical trial","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"issue":"10","key":"2026071419565723500_bnag006-B120","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1080\/14656566.2019.1615882","article-title":"Bazedoxifene for the treatment of osteoporosis","volume":"20","author":"Yavropoulou","year":"2019","journal-title":"Exp Opin Pharmacother"},{"issue":"8","key":"2026071419565723500_bnag006-B121","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJMoa0808692","article-title":"Lasofoxifene in postmenopausal women with osteoporosis","volume":"362","author":"Cummings","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"2026071419565723500_bnag006-B122","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1007\/s00198-017-4132-y","article-title":"Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users","volume":"28","author":"Eiken","year":"2017","journal-title":"Osteoporos Int"},{"issue":"5","key":"2026071419565723500_bnag006-B123","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00198-014-2624-6","article-title":"Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population","volume":"25","author":"Lin","year":"2014","journal-title":"Osteoporos Int"},{"issue":"8","key":"2026071419565723500_bnag006-B124","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJMoa1916525","article-title":"Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates","volume":"383","author":"Black","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"2026071419565723500_bnag006-B125","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.injury.2007.08.036","article-title":"An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?","volume":"39","author":"Kwek","year":"2008","journal-title":"Injury"},{"key":"2026071419565723500_bnag006-B126","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1302\/0301-620X.89B3.18146","article-title":"Subtrochanteric insufficiency fractures in patients on alendronate therapy\u2014a caution","volume":"89B","author":"Goh","year":"2007","journal-title":"J Bone Joint Surg Br"},{"issue":"12","key":"2026071419565723500_bnag006-B127","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMc0707493","article-title":"Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate","volume":"358","author":"Lenart","year":"2008","journal-title":"N Engl J Med"},{"issue":"8","key":"2026071419565723500_bnag006-B128","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1210\/jc.2007-2803","article-title":"Severely suppressed bone turnover and atypical skeletal fragility","volume":"93","author":"Visekruna","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026071419565723500_bnag006-B129","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026071419565723500_bnag006-B130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research","volume":"29","author":"Shane","year":"2014","journal-title":"J Bone Miner Res"},{"key":"2026071419565723500_bnag006-B131","doi-asserted-by":"crossref","first-page":"116297","DOI":"10.1016\/j.bone.2021.116297","article-title":"Bisphosphonates and the risk of atypical femur fractures","volume":"156","author":"Black","year":"2022","journal-title":"Bone"},{"issue":"11","key":"2026071419565723500_bnag006-B132","doi-asserted-by":"crossref","first-page":"e2141","DOI":"10.1210\/clinem\/dgae023","article-title":"Bisphosphonate use and risk of atypical femoral fractures: a Danish case cohort study with blinded radiographic review","volume":"109","author":"Bauer","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071419565723500_bnag006-B133","first-page":"s120","article-title":"Resolution of effects on bone turnover markers and bone mineral density after discontinuation of long-term bisphosphonate use","volume":"27","author":"Langdahl","year":"2012","journal-title":"J Bone Min Res"},{"issue":"3","key":"2026071419565723500_bnag006-B134","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S8756-3282(03)00112-1","article-title":"Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal","volume":"33","author":"Bagger","year":"2003","journal-title":"Bone"},{"issue":"5","key":"2026071419565723500_bnag006-B135","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/MLR.0000000000001294","article-title":"Duration of bisphosphonate drug holidays and associated fracture risk","volume":"58","author":"Curtis","year":"2020","journal-title":"Med Care"},{"issue":"7","key":"2026071419565723500_bnag006-B136","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/jbmr.3420","article-title":"Bisphosphonate drug holiday and fracture risk: a population-based cohort study","volume":"33","author":"Adams","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2026071419565723500_bnag006-B137","doi-asserted-by":"crossref","first-page":"100301","DOI":"10.1016\/j.jbo.2020.100301","article-title":"Incidence of atypical femoral fractures in the treatment of bone metastasis: an alert report","volume":"23","author":"Kaku","year":"2020","journal-title":"J Bone Oncol"},{"issue":"4","key":"2026071419565723500_bnag006-B138","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00198-018-04823-5","article-title":"Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis","volume":"30","author":"Naylor","year":"2019","journal-title":"Osteoporos Int"},{"issue":"10","key":"2026071419565723500_bnag006-B139","doi-asserted-by":"crossref","first-page":"e10681","DOI":"10.1002\/jbm4.10681","article-title":"Incidence of atypical femoral fractures in patients on osteoporosis therapy\u2014a registry-based cohort study","volume":"6","author":"Everts-Graber","year":"2022","journal-title":"JBMR Plus"},{"issue":"5","key":"2026071419565723500_bnag006-B140","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofacial Surg"},{"issue":"35","key":"2026071419565723500_bnag006-B141","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026071419565723500_bnag006-B142","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"22","key":"2026071419565723500_bnag006-B143","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1056\/NEJMp068157","article-title":"Osteonecrosis of the jaw\u2014do bisphosphonates pose a risk?","volume":"355","author":"Bilezikian","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"2026071419565723500_bnag006-B144","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00198-024-07262-7","article-title":"Treatment for osteoporosis and risk of osteonecrosis of the jaw among female patients in the United Kingdom clinical practice research datalink","volume":"36","author":"Persson","year":"2025","journal-title":"Osteoporos Int"},{"issue":"1","key":"2026071419565723500_bnag006-B145","doi-asserted-by":"crossref","first-page":"23","DOI":"10.14219\/jada.archive.2008.0016","article-title":"Bisphosphonate use and the risk of adverse jaw outcomes","volume":"139","author":"Cartsos","year":"2008","journal-title":"J Am Dent Assoc"},{"issue":"6","key":"2026071419565723500_bnag006-B146","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00198-007-0502-1","article-title":"Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker","volume":"19","author":"Pazianas","year":"2008","journal-title":"Osteoporos Int"},{"issue":"4","key":"2026071419565723500_bnag006-B147","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ecl.2024.08.007","article-title":"Diagnosis and management of atypical femoral fractures and medication-related osteonecrosis of the jaw in patients with osteoporosis","volume":"53","author":"Alnajmi","year":"2024","journal-title":"Endocrinol Metab Clin N Amer"},{"issue":"5","key":"2026071419565723500_bnag006-B148","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.joms.2009.01.003","article-title":"Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies","volume":"67","author":"Assael","year":"2009","journal-title":"J Oral Maxillofacial Surg"},{"issue":"3","key":"2026071419565723500_bnag006-B149","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijom.2010.11.002","article-title":"Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis","volume":"40","author":"Manfredi","year":"2011","journal-title":"Int J Oral Maxillofacial Surg"},{"issue":"26","key":"2026071419565723500_bnag006-B150","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.19.02192","article-title":"Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial","volume":"38","author":"Sim","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026071419565723500_bnag006-B151","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American association of oral and maxillofacial surgeons' position paper on medication-related osteonecrosis of the jaws\u20142022 update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J Oral Maxillofacial Surg"},{"issue":"9077","key":"2026071419565723500_bnag006-B152","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet"},{"issue":"19","key":"2026071419565723500_bnag006-B153","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"10102","key":"2026071419565723500_bnag006-B154","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"2026071419565723500_bnag006-B155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2018.09.020","article-title":"Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis","volume":"120","author":"D\u00edez-P\u00e9rez","year":"2019","journal-title":"Bone"},{"issue":"6","key":"2026071419565723500_bnag006-B156","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00198-025-07440-1","article-title":"PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis","volume":"36","author":"Beaudart","year":"2025","journal-title":"Osteoporos Int"},{"issue":"1","key":"2026071419565723500_bnag006-B157","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"20","key":"2026071419565723500_bnag006-B158","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"issue":"10117","key":"2026071419565723500_bnag006-B159","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"key":"2026071419565723500_bnag006-B160","first-page":"e068033","article-title":"Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials","volume":"381","author":"H\u00e4ndel","year":"2023","journal-title":"BMJ (Clinical Research Ed)"},{"issue":"9","key":"2026071419565723500_bnag006-B161","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1210\/jc.2011-3479","article-title":"Randomized teriparatide human parathyroid hormone (PTH) 1-34 once-weekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk","volume":"97","author":"Nakamura","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026071419565723500_bnag006-B162","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/jbmr.4188","article-title":"Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study","volume":"36","author":"Gilsenan","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2026071419565723500_bnag006-B163","doi-asserted-by":"crossref","first-page":"e10665","DOI":"10.1002\/jbm4.10665","article-title":"Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates","volume":"6","author":"Krege","year":"2022","journal-title":"JBMR Plus"},{"issue":"3","key":"2026071419565723500_bnag006-B164","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s43441-024-00616-7","article-title":"Real-world evidence to support the registration of a new osteoporosis medicinal product in Europe","volume":"58","author":"Davenport","year":"2024","journal-title":"Ther Innov Regul Sci"},{"issue":"2","key":"2026071419565723500_bnag006-B165","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bcp.13455","article-title":"Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism\u2014translating the pharmacology","volume":"84","author":"Tay","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"2026071419565723500_bnag006-B166","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"issue":"8","key":"2026071419565723500_bnag006-B167","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026071419565723500_bnag006-B168","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00198-022-06413-y","article-title":"Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: a US administrative claims database study","volume":"33","author":"Cosman","year":"2022","journal-title":"Osteoporos Int"},{"issue":"2","key":"2026071419565723500_bnag006-B169","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.eprac.2024.10.017","article-title":"Comparative effectiveness of abaloparatide and teriparatide in women 50 years of age and older: update of a real-world retrospective analysis","volume":"31","author":"Tabatabai","year":"2025","journal-title":"Endocr Pract"},{"key":"2026071419565723500_bnag006-B170","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.yrtph.2017.04.001","article-title":"Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1\u201334)","volume":"86","author":"Jolette","year":"2017","journal-title":"Reg Toxicol Pharmacol"},{"issue":"10","key":"2026071419565723500_bnag006-B171","doi-asserted-by":"crossref","first-page":"e25900","DOI":"10.1371\/journal.pone.0025900","article-title":"Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway","volume":"6","author":"Wijenayaka","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"2026071419565723500_bnag006-B172","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"2026071419565723500_bnag006-B173","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study","volume":"33","author":"McClung","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2026071419565723500_bnag006-B174","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1007\/s00198-019-05146-9","article-title":"Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab","volume":"30","author":"Kendler","year":"2019","journal-title":"Osteoporos Int"},{"issue":"11","key":"2026071419565723500_bnag006-B175","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1007\/s00198-020-05502-0","article-title":"A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab","volume":"31","author":"McClung","year":"2020","journal-title":"Osteoporos Int"},{"issue":"9","key":"2026071419565723500_bnag006-B176","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/jbmr.3735","article-title":"Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment","volume":"34","author":"Chavassieux","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"16","key":"2026071419565723500_bnag006-B177","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"2026071419565723500_bnag006-B178","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis","volume":"103","author":"Michael Lewiecki","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026071419565723500_bnag006-B179","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"15","key":"2026071419565723500_bnag006-B180","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"2026071419565723500_bnag006-B181","doi-asserted-by":"crossref","first-page":"104697","DOI":"10.1016\/j.yrtph.2020.104697","article-title":"Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture","volume":"115","author":"Turk","year":"2020","journal-title":"Reg Toxicol Pharmacol"},{"issue":"7","key":"2026071419565723500_bnag006-B182","doi-asserted-by":"crossref","first-page":"E187","DOI":"10.1161\/ATVBAHA.122.317635","article-title":"Role of sclerostin in cardiovascular disease","volume":"42","author":"Golledge","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026071419565723500_bnag006-B183","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.bonr.2018.01.005","article-title":"The roles of vitamin D and dietary calcium in nutritional rickets","volume":"8","author":"Thandrayen","year":"2018","journal-title":"Bone Rep"},{"key":"2026071419565723500_bnag006-B184","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/164_2019_324","article-title":"Calcium and bone","volume":"262","author":"Reid","year":"2020","journal-title":"Handb Exp Pharmacol"},{"issue":"9","key":"2026071419565723500_bnag006-B185","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1007\/s00198-012-1964-3","article-title":"A systematic review of hip fracture incidence and probability of fracture worldwide","volume":"23","author":"Kanis","year":"2012","journal-title":"Osteoporos Int"},{"key":"2026071419565723500_bnag006-B186","volume-title":"Handbook on Human Nutritional Requirments","author":"Food and Agriculture Organisation of the United Nations, World Health Organisation","year":"1974"},{"issue":"10","key":"2026071419565723500_bnag006-B187","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1093\/ajcn\/30.10.1603","article-title":"Calcium balance and calcium requirements in middle-aged women","volume":"30","author":"Heaney","year":"1977","journal-title":"Am J Clin Nutr"},{"key":"2026071419565723500_bnag006-B188","first-page":"953","article-title":"Menopausal changes in calcium balance performance","volume":"92","author":"Heaney","year":"1978","journal-title":"J Lab Clin Med"},{"key":"2026071419565723500_bnag006-B189","doi-asserted-by":"crossref","first-page":"e082963","DOI":"10.1136\/bmj-2024-082963","article-title":"Wash-in and washout effects: mitigating bias in short term dietary and other trials","volume":"389","author":"Ludwig","year":"2025","journal-title":"BMJ"},{"issue":"4","key":"2026071419565723500_bnag006-B190","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/joim.12394","article-title":"Calcium supplements: benefits and risks","volume":"278","author":"Reid","year":"2015","journal-title":"J Intern Med"},{"issue":"8","key":"2026071419565723500_bnag006-B191","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1210\/jc.2019-00111","article-title":"Dietary calcium intake and bone loss over 6 years in osteopenic postmenopausal women","volume":"104","author":"Bristow","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026071419565723500_bnag006-B192","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.amjmed.2006.02.038","article-title":"Randomized controlled trial of calcium in healthy older women","volume":"119","author":"Reid","year":"2006","journal-title":"Am J Med"},{"issue":"4","key":"2026071419565723500_bnag006-B193","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/ajcn\/86.4.1054","article-title":"Calcium requirements: new estimations for men and women by cross-sectional statistical analyses of calcium balance data from metabolic studies","volume":"86","author":"Hunt","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"2026071419565723500_bnag006-B194","first-page":"776","article-title":"Habitual dietary calcium intakes and calcium metabolism in healthy adults Chinese: a systematic review and meta-analysis","volume":"25","author":"Fang","year":"2016","journal-title":"Asia Pacific J Clin Nutr"},{"issue":"10","key":"2026071419565723500_bnag006-B195","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1017\/S0007114517001301","article-title":"Dietary calcium intake and rate of bone loss in men","volume":"117","author":"Bristow","year":"2017","journal-title":"Br J Nutr"},{"issue":"12","key":"2026071419565723500_bnag006-B196","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1210\/jc.2012-1407","article-title":"Calcium intakes and femoral and lumbar bone density of elderly U.S. Men and women: national health and nutrition examination survey 2005-2006 analysis","volume":"97","author":"Anderson","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026071419565723500_bnag006-B197","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/ajcn\/86.5.1780","article-title":"Calcium intake and hip fracture risk in men and women: a meta-analysis of prospective cohort studies and randomized controlled trials","volume":"86","author":"Bischoff-Ferrari","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"2026071419565723500_bnag006-B198","doi-asserted-by":"crossref","first-page":"h4580","DOI":"10.1136\/bmj.h4580","article-title":"Calcium intake and risk of fracture: systematic review","volume":"351","author":"Bolland","year":"2015","journal-title":"BMJ"},{"issue":"1","key":"2026071419565723500_bnag006-B199","first-page":"CD012664","article-title":"Calcium and vitamin D for increasing bone mineral density in premenopausal women","volume":"1","author":"M\u00e9ndez-S\u00e1nchez","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2026071419565723500_bnag006-B200","doi-asserted-by":"crossref","first-page":"h4183","DOI":"10.1136\/bmj.h4183","article-title":"Calcium intake and bone mineral density: systematic review and meta-analysis","volume":"351","author":"Tai","year":"2015","journal-title":"BMJ"},{"issue":"8","key":"2026071419565723500_bnag006-B201","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","article-title":"Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials","volume":"8","author":"Black","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"2026071419565723500_bnag006-B202","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1001\/jama.2017.19344","article-title":"Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults: a systematic review and meta-analysis","volume":"318","author":"Zhao","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"2026071419565723500_bnag006-B203","doi-asserted-by":"crossref","first-page":"e10246","DOI":"10.1002\/jbm4.10246","article-title":"Calcium supplement use is associated with less bone mineral density loss, but does not lessen the risk of bone fracture across the menopause transition: data from the study of Women's health across the nation","volume":"4","author":"Bailey","year":"2020","journal-title":"JBMR Plus"},{"issue":"15","key":"2026071419565723500_bnag006-B204","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2017.21640","article-title":"Vitamin D, calcium, OR combined supplementation for the primary prevention of fractures in community-dwelling adults evidence report and systematic review for the US preventive services task force","volume":"319","author":"Kahwati","year":"2018","journal-title":"JAMA"},{"issue":"15","key":"2026071419565723500_bnag006-B205","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1001\/jama.2018.3185","article-title":"Vitamin D, calcium, OR combined supplementation for the primary prevention of fractures in community-dwelling adults. US preventive services task force recommendation statement","volume":"319","author":"Grossman","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"2026071419565723500_bnag006-B206","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00198-016-3773-6","article-title":"The role of calcium supplementation in healthy musculoskeletal ageing: an expert consensus meeting of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO) and the international foundation for osteoporosis (IOF)","volume":"28","author":"Harvey","year":"2017","journal-title":"Osteoporos Int"},{"issue":"3","key":"2026071419565723500_bnag006-B207","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/jbmr.1484","article-title":"Adverse events from calcium supplementation: relationship to errors in myocardial infarction self-reporting in randomized controlled trials of calcium supplementation","volume":"27","author":"Lewis","year":"2012","journal-title":"J Bone Min Res"},{"issue":"11","key":"2026071419565723500_bnag006-B208","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/GME.0000000000000270","article-title":"Incidence of hypercalciuria and hypercalcemia during vitamin D and calcium supplementation in older women","volume":"21","author":"Gallagher","year":"2014","journal-title":"Menopause"},{"key":"2026071419565723500_bnag006-B209","doi-asserted-by":"crossref","first-page":"C3691","DOI":"10.1136\/bmj.c3691","article-title":"Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis","volume":"341","author":"Bolland","year":"2010","journal-title":"BMJ"},{"key":"2026071419565723500_bnag006-B210","doi-asserted-by":"crossref","first-page":"d2040","DOI":"10.1136\/bmj.d2040","article-title":"Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's health initiative limited access dataset and meta-analysis","volume":"342","author":"Bolland","year":"2011","journal-title":"BMJ"},{"issue":"10","key":"2026071419565723500_bnag006-B211","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1017\/S0007114514002785","article-title":"Acute and 3-month effects of microcrystalline hydroxyapatite, calcium citrate and calcium carbonate on serum calcium and markers of bone turnover: a randomised controlled trial in postmenopausal women","volume":"112","author":"Bristow","year":"2014","journal-title":"Br J Nutr"},{"issue":"3","key":"2026071419565723500_bnag006-B212","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00198-015-3372-y","article-title":"Acute and 3-month effects of calcium carbonate on the calcification propensity of serum and regulators of vascular calcification: secondary analysis of a randomized controlled trial","volume":"27","author":"Bristow","year":"2016","journal-title":"Osteoporos Int"},{"issue":"11","key":"2026071419565723500_bnag006-B213","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1017\/S0007114515003694","article-title":"Acute effects of calcium supplements on blood pressure and blood coagulation: secondary analysis of a randomised controlled trial in post-menopausal women","volume":"114","author":"Bristow","year":"2015","journal-title":"Br J Nutr"},{"issue":"1","key":"2026071419565723500_bnag006-B214","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00198-016-3744-y","article-title":"Acute effects of calcium supplements on blood pressure: randomised, crossover trial in postmenopausal women","volume":"28","author":"Billington","year":"2017","journal-title":"Osteoporos Int"},{"issue":"6","key":"2026071419565723500_bnag006-B215","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/joim.12464","article-title":"Circulating calcium concentrations, vascular disease and mortality: a systematic review","volume":"279","author":"Reid","year":"2016","journal-title":"J Intern Med"},{"issue":"4","key":"2026071419565723500_bnag006-B216","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1001\/jama.2017.8981","article-title":"Association of genetic variants related to Serum calcium levels with coronary artery disease and myocardial infarction","volume":"318","author":"Larsson","year":"2017","journal-title":"JAMA"},{"key":"2026071419565723500_bnag006-B217","doi-asserted-by":"crossref","first-page":"103865","DOI":"10.1016\/j.ebiom.2022.103865","article-title":"Health effects of high serum calcium levels: updated phenome-wide Mendelian randomisation investigation and review of Mendelian randomisation studies","volume":"76","author":"Yuan","year":"2022","journal-title":"eBioMedicine"},{"issue":"11","key":"2026071419565723500_bnag006-B218","doi-asserted-by":"crossref","first-page":"e10542","DOI":"10.1002\/jbm4.10542","article-title":"Health effects of calcium: evidence from Mendelian randomization studies","volume":"5","author":"Chen","year":"2021","journal-title":"JBMR Plus"},{"issue":"1","key":"2026071419565723500_bnag006-B219","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/jbmr.2311","article-title":"The effects of calcium supplementation on verified coronary heart disease hospitalization and death in postmenopausal women: a collaborative meta-analysis of randomized controlled trials","volume":"30","author":"Lewis","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2026071419565723500_bnag006-B220","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijcard.2013.08.055","article-title":"Effect of calcium or vitamin D supplementation on vascular outcomes: a meta-analysis of randomized controlled trials","volume":"169","author":"Mao","year":"2013","journal-title":"Int J Cardiol"},{"issue":"4","key":"2026071419565723500_bnag006-B221","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/07315724.2019.1649219","article-title":"The evidence and controversy between dietary calcium intake and calcium supplementation and the risk of cardiovascular disease: a systematic review and meta-analysis of cohort studies and randomized controlled trials","volume":"39","author":"Yang","year":"2020","journal-title":"J Amer Coll Nutr"},{"issue":"6","key":"2026071419565723500_bnag006-B222","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1185\/030079907X188035","article-title":"Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density","volume":"23","author":"Bonnick","year":"2007","journal-title":"Curr Med Res Opinion"},{"issue":"13","key":"2026071419565723500_bnag006-B223","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Effects of estrogen plus progestin on risk of fracture and bone mineral density\u2014the Women's health initiative randomized trial","volume":"290","author":"Cauley","year":"2003","journal-title":"JAMA"},{"issue":"1","key":"2026071419565723500_bnag006-B224","doi-asserted-by":"crossref","first-page":"29","DOI":"10.7326\/M24-0013","article-title":"The effect of denosumab on risk for emergently treated hypocalcemia by stage of chronic kidney disease","volume":"178","author":"Bird","year":"2025","journal-title":"Ann Intern Med"},{"issue":"4","key":"2026071419565723500_bnag006-B225","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-128-4-199802150-00001","article-title":"Alendronate prevents postmenopausal bone loss in women without osteoporosis\u2014a double-blind, randomized, controlled trial","volume":"128","author":"McClung","year":"1998","journal-title":"Ann Intern Med"},{"issue":"3","key":"2026071419565723500_bnag006-B226","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.gme.0000188736.69617.4f","article-title":"Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene","volume":"13","author":"McClung","year":"2006","journal-title":"Menopause"},{"issue":"8","key":"2026071419565723500_bnag006-B227","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00198-007-0343-y","article-title":"The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women","volume":"18","author":"Kanis","year":"2007","journal-title":"Osteoporos Int"},{"issue":"8","key":"2026071419565723500_bnag006-B228","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00198-007-0362-8","article-title":"Development of a nomogram for individualizing hip fracture risk in men and women","volume":"18","author":"Nguyen","year":"2007","journal-title":"Osteoporos Int"},{"issue":"9321","key":"2026071419565723500_bnag006-B229","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(02)08761-5","article-title":"Diagnosis of osteoporosis and assessment of fracture risk","volume":"359","author":"Kanis","year":"2002","journal-title":"Lancet"},{"issue":"11","key":"2026071419565723500_bnag006-B230","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S2213-8587(24)00225-0","article-title":"Osteopenia: a key target for fracture prevention","volume":"12","author":"Reid","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9992","key":"2026071419565723500_bnag006-B231","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"2026071419565723500_bnag006-B232","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1359\/jbmr.070904","article-title":"Effects of raloxifene on fracture risk in postmenopausal women: the raloxifene use for the heart trial","volume":"23","author":"Ensrud","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2026071419565723500_bnag006-B233","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/jbmr\/zjae068","article-title":"Pre-treatment bone mineral density (BMD) and the benefit of pharmacologic treatment on fracture risk and BMD change: analysis from the FNIH-ASBMR SABRE project","volume":"39","author":"Schini","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2026071419565723500_bnag006-B234","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician's guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff","year":"2022","journal-title":"Osteoporos Int"},{"issue":"4","key":"2026071419565723500_bnag006-B235","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00198-007-0550-6","article-title":"Cost-effective osteoporosis treatment thresholds: the United States perspective","volume":"19","author":"Tosteson","year":"2008","journal-title":"Osteoporos Int"},{"key":"2026071419565723500_bnag006-B236","author":"National Institute for Health and Care Excellence","year":"2017"},{"issue":"1","key":"2026071419565723500_bnag006-B237","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11657-019-0660-8","article-title":"Comparison of treatment strategies and thresholds for optimizing fracture prevention in Canada: a simulation analysis","volume":"15","author":"Leslie","year":"2020","journal-title":"Arch Osteoporos"},{"issue":"9","key":"2026071419565723500_bnag006-B238","doi-asserted-by":"crossref","first-page":"afad172","DOI":"10.1093\/ageing\/afad172","article-title":"Call to action: a five nations consensus on the use of intravenous zoledronate after hip fracture","volume":"52","author":"Johansen","year":"2023","journal-title":"Age Ageing"},{"issue":"1","key":"2026071419565723500_bnag006-B239","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jbmr.2315","article-title":"Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT study","volume":"30","author":"Tsai","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2026071419565723500_bnag006-B240","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1\u201334)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J Bone Min Res"},{"issue":"3","key":"2026071419565723500_bnag006-B241","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00198-020-05780-8","article-title":"Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden","volume":"32","author":"S\u00f6reskog","year":"2021","journal-title":"Osteoporos Int"},{"key":"2026071419565723500_bnag006-B242","doi-asserted-by":"crossref","first-page":"115158","DOI":"10.1016\/j.bone.2019.115158","article-title":"The effect of bisphosphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: the T-score bone marker approach in the TRIO study","volume":"131","author":"Gossiel","year":"2020","journal-title":"Bone"},{"issue":"1","key":"2026071419565723500_bnag006-B243","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00198-015-3145-7","article-title":"Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study","volume":"27","author":"Naylor","year":"2016","journal-title":"Osteoporos Int"},{"issue":"3","key":"2026071419565723500_bnag006-B244","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1210\/jc.2003-030501","article-title":"The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial","volume":"89","author":"Clowes","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026071419565723500_bnag006-B245","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1210\/jc.2006-1526","article-title":"Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis","volume":"92","author":"Delmas","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026071419565723500_bnag006-B246","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00198-020-05734-0","article-title":"Real-world bone turnover marker use: impact on treatment decisions and fracture","volume":"32","author":"Lane","year":"2021","journal-title":"Osteoporos Int"},{"issue":"10","key":"2026071419565723500_bnag006-B247","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/jbmr.3813","article-title":"Association of bone density monitoring in routine clinical practice with anti-osteoporosis medication use and incident fractures: a matched cohort study","volume":"34","author":"Leslie","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2026071419565723500_bnag006-B248","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/jbmr.4333","article-title":"Patient outcomes in the years after a DXA-BMD treatment-monitoring test: improved medication adherence in some, but too little too late","volume":"36","author":"Kline","year":"2021","journal-title":"J Bone Mineral Res"},{"issue":"1","key":"2026071419565723500_bnag006-B249","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/jbmr.4167","article-title":"Predictors of fracture in older women with osteopenic hip bone mineral density treated with zoledronate","volume":"36","author":"Reid","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2026071419565723500_bnag006-B250","doi-asserted-by":"crossref","first-page":"e3877","DOI":"10.1210\/clinem\/dgac324","article-title":"Repeat bone mineral density screening measurement and fracture prediction in older men: a prospective cohort study","volume":"107","author":"Ensrud","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026071419565723500_bnag006-B251","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/jbmr.3194","article-title":"The ability of a single BMD and fracture history assessment to predict fracture over 25 years in postmenopausal women: the study of osteoporotic fractures","volume":"33","author":"Black","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2026071419565723500_bnag006-B252","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/jbmr\/zjaf014","article-title":"Probability of achieving bone mineral density treatment goals with denosumab treatment in postmenopausal women with osteoporosis","volume":"40","author":"Cosman","year":"2025","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2026071419565723500_bnag006-B253","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","article-title":"Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024","volume":"39","author":"Cosman","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2026071419565723500_bnag006-B254","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/jbmr.3722","article-title":"Relationship between bone mineral density T-score and nonvertebral fracture risk over 10 years of denosumab treatment","volume":"34","author":"Ferrari","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2026071419565723500_bnag006-B255","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/jbmr.3996","article-title":"T-Score as an indicator of fracture risk during treatment with romosozumab or alendronate in the ARCH trial","volume":"35","author":"Cosman","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026071419565723500_bnag006-B256","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11914-025-00909-2","article-title":"Sequential and long-term therapy for osteoporosis","volume":"23","author":"McClung","year":"2025","journal-title":"Curr Osteoporos Rep"},{"issue":"5","key":"2026071419565723500_bnag006-B257","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/jbmr.11","article-title":"Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial","volume":"25","author":"Schwartz","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026071419565723500_bnag006-B258","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/jbmr.2023","article-title":"Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW)","volume":"29","author":"D\u00edez-P\u00e9rez","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2026071419565723500_bnag006-B259","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026071419565723500_bnag006-B260","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1359\/jbmr.081250","article-title":"Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate","volume":"24","author":"Cosman","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2026071419565723500_bnag006-B261","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/jbmr\/zjae196","article-title":"Verifying the effectiveness of romosozumab re-administration on bone mineral density","volume":"40","author":"Kobayakawa","year":"2025","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2026071419565723500_bnag006-B262","doi-asserted-by":"crossref","first-page":"ziae131","DOI":"10.1093\/jbmrpl\/ziae131","article-title":"Therapy with transitions from one bone-forming agent to another: a retrospective cohort study on teriparatide and romosozumab","volume":"8","author":"Kobayakawa","year":"2024","journal-title":"JBMR Plus"},{"issue":"7","key":"2026071419565723500_bnag006-B263","doi-asserted-by":"crossref","first-page":"e10512","DOI":"10.1002\/jbm4.10512","article-title":"Skeletal responses to romosozumab after 12 months of denosumab","volume":"5","author":"McClung","year":"2021","journal-title":"JBMR Plus"},{"issue":"1","key":"2026071419565723500_bnag006-B264","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jbmr.3877","article-title":"Secondary fracture prevention: consensus clinical recommendations from a multistakeholder coalition","volume":"35","author":"Conley","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2026071419565723500_bnag006-B265","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00198-024-07052-1","article-title":"Effectiveness of fracture liaison service in reducing the risk of secondary fragility fractures in adults aged 50 and older: a systematic review and meta-analysis","volume":"35","author":"Danazumi","year":"2024","journal-title":"Osteoporos Int"},{"issue":"6","key":"2026071419565723500_bnag006-B266","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00198-024-07027-2","article-title":"Return on investment of fracture liaison services: a systematic review and analysis","volume":"35","author":"Xu","year":"2024","journal-title":"Osteoporos Int"},{"issue":"2","key":"2026071419565723500_bnag006-B267","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMp2409086","article-title":"Coordinating multidisciplinary care\u2014improving outcomes after fragility fractures","volume":"392","author":"Napoli","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/edrv\/advance-article-pdf\/doi\/10.1210\/endrev\/bnag006\/67125105\/bnag006.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/advance-article-pdf\/doi\/10.1210\/endrev\/bnag006\/67125105\/bnag006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/advance-article-pdf\/doi\/10.1210\/endrev\/bnag006\/67125105\/bnag006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:57:36Z","timestamp":1784073456000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/47\/4\/468\/8498994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":267,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2,26]]},"published-print":{"date-parts":[[2026,7,15]]}},"URL":"https:\/\/doi.org\/10.1210\/endrev\/bnag006","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,2,26]]}}}